Dr Reddy’s Swallows Up Mayne’s US Generics Portfolio For $90m+
Indian Firm Strikes Deal For US Prescription Interests Of Australian Player
Dr Reddy’s has struck a deal to pay at least $90m for the US prescription generics portfolio of Mayne Pharma. The transaction covers products including Mayne’s recently-launched rival to NuvaRing.
